http://jcps.bjmu.edu.cn

中国药学(英文版) ›› 2021, Vol. 30 ›› Issue (3): 266-266.

• 【 其 它 】 • 上一篇    

Cover story of JCPS 2021-3

齐宪荣课题组   

  1. 北京大学医学部 药学院 药剂学系, 北京 100191
  • 出版日期:2021-03-29 发布日期:2021-03-31

2021年第3期JCPS封面故事

Xianrong Qi group   

  1. Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
  • Online:2021-03-29 Published:2021-03-31

摘要:

SDF-1/CXCR4是与癌症转移最相关的趋化因子通路之一, 因此靶向CXCR4的siRNA能够改善高转移性癌症治疗效果, 尤其将其与化疗联合使用时潜力巨大。本研究中, 我们构建了核黄素修饰的脂质复合纳米粒(PhD/siRNA/lip-RF), 实现了对CXCR4 siRNA和阿霉素的共递送。正电性的酸敏感阿霉素前药(PEI-hyd-DOX, PhD)与负电性的siRNA紧密压缩形成聚合物纳米粒, 进一步以尾端含核黄素的脂质薄膜对其进行包覆, 制备得到核黄素修饰的脂质复合纳米粒, 即PhD/siRNA/lip-RF。 PhD/siRNA/lip-RF被肿瘤细胞高效摄取, 并在体内有效制了原位肿瘤的生长和肿瘤转移。

Abstract:

SDF-1/CXCR4 is one of the most relevant chemokine signaling pathways to cancer metastasis, and siRNA targeting CXCR4 may provide potential improvements to treat those highly metastatic cancers, especially when combined with chemotherapy. A riboflavin-modified lipo-polyplexes to co-deliver CXCR4 siRNA and doxorubicin (PhD/siRNA/lip-RF) were constructed conveniently by acid-sensitive cationic prodrug (PEI-hyd-DOX, PhD) condensed with anionic siRNA to form PhD/siRNA polyplexes, which were further coated with riboflavin-tailed lipid-membrane. The PhD/siRNA/lip-RF were effectively taken into tumor cells and inhibited primary tumor growth and tumor metastasis in vivo.

Supporting: